WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555866
Description: HUN20688, also known as TXNRD1 inhibitor 1 ands TRi-1, is a potent, specific and irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1). TXNRD1 inhibitor 1 (TRi-1) impaired growth and viability of human tumor xenografts and syngeneic mouse tumors while having little mitochondrial toxicity and being better tolerated than auranofin. These results display the therapeutic anticancer potential of irreversibly targeting cytosolic TXNRD1 using small molecules and present potent and selective TXNRD1 inhibitors. Given the pronounced up-regulation of TXNRD1 in several metastatic malignancies, it seems worthwhile to further explore the potential benefit of specific irreversible TXNRD1 inhibitors for anticancer therapy.
MedKoo Cat#: 555866
Chemical Formula: C13H10ClNO5S
Exact Mass: 326.9968
Molecular Weight: 327.735
Elemental Analysis: C, 47.64; H, 3.08; Cl, 10.82; N, 4.27; O, 24.41; S, 9.78
Synonym: TXNRD1 inhibitor 1; TRi-1; HUN20688; HUN-20688; HUN 20688;
IUPAC/Chemical Name: 2-((4-chlorophenyl)sulfonyl)-4-methoxy-1-nitrobenzene
InChi Key: HURFJQIYDCUMPC-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H10ClNO5S/c1-20-10-4-7-12(15(16)17)13(8-10)21(18,19)11-5-2-9(14)3-6-11/h2-8H,1H3
SMILES Code: O=[N+](C1=CC=C(OC)N=C1S(=O)(C2=CC=C(Cl)C=C2)=O)[O-]
Cancer cells adapt to their inherently increased oxidative stress through activation of the glutathione (GSH) and thioredoxin (TXN) systems. Inhibition of both of these systems effectively kills cancer cells, but such broad inhibition of antioxidant activity also kills normal cells, which is highly unwanted in a clinical setting.
HUN20688 has CAS#246020-68-8, no formal name. For the convenience of scientific communication, we named it as HUN20688 (combined from Inchi key plus CAS#) according to Hodoodo Chemical Nomenclature (https://hodoodo.com/hodoodo-chemical-nomenclature).
. Stafford WC, et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med. 2018 Feb 14;10(428). pii: eaaf7444.